IRS2 and lung adenocarcinoma: Specifically, Irs2 was upregulated (p < 0.05) in colon adenocarcinoma (COAD), kidney chromophobe (KICH) and rectum adenocarcinoma (READ) but downregulated (p < 0.05) in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG) and uterine corpus endometrial carcinoma (UCEC).